Ebola virus: unravelling pathogenesis to combat a deadly disease

被引:121
作者
Hoenen, Thomas
Groseth, Allison
Falzarano, Darryl
Feldmann, Heinz
机构
[1] Publ Hlth Agcy Canada, Special Pathogens Program, Natl Microbiol Lab, Winnipeg, MB R3E 3R2, Canada
[2] Univ Marburg, Inst Virol, D-35037 Marburg, Germany
[3] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E 0W3, Canada
关键词
D O I
10.1016/j.molmed.2006.03.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ebola virus (EBOV) causes severe haemorrhagic fever leading to up to 90% lethality. Increasingly frequent outbreaks and the placement of EBOV in the category A list of potential biothreat agents have boosted interest in this virus. Furthermore, development of new technologies (e.g. reverse genetics systems) and extensive studies on Ebola haemorrhagic fever (EHF) in animal models have substantially expanded the knowledge on the pathogenic mechanisms that underlie this disease. Two major factors in EBOV pathogenesis are the impairment of the immune response and vascular dysfunction. Here, we attempt to summarize the current knowledge on EBOV pathogenesis focusing on these two factors and on recent progress in the development of vaccines and potential therapeutics.
引用
收藏
页码:206 / 215
页数:10
相关论文
共 95 条
[41]   Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily [J].
Hensley, LE ;
Young, HA ;
Jahrling, PB ;
Geisbert, TW .
IMMUNOLOGY LETTERS, 2002, 80 (03) :169-179
[42]  
Ignatyev GM, 1999, CURR TOP MICROBIOL, V235, P205
[43]   Ebola virus glycoprotein: Proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies [J].
Ito, H ;
Watanabe, S ;
Takada, A ;
Kawaoka, Y .
JOURNAL OF VIROLOGY, 2001, 75 (03) :1576-1580
[44]   Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections [J].
Jahrling, PB ;
Geisbert, TW ;
Geisbert, JB ;
Swearengen, JR ;
Bray, M ;
Jaax, NK ;
Huggins, JW ;
LeDuc, JW ;
Peters, CJ .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 :S224-S234
[45]  
Jahrling PB, 1996, ARCH VIROL, P135
[46]   Ebola between outbreaks: Intensified Ebola hemorrhagic fever surveillance in the Democratic Republic of the Congo, 1981-1985 [J].
Jezek, Z ;
Szczeniowski, MY ;
Muyembe-Tamfum, JJ ;
McCormick, JB ;
Heymann, DL .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 :S60-S64
[47]   Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses [J].
Jones, SM ;
Feldmann, H ;
Ströher, U ;
Geisbert, JB ;
Fernando, L ;
Grolla, A ;
Klenk, HD ;
Sullivan, NJ ;
Volchkov, VE ;
Fritz, EA ;
Daddario, KM ;
Hensley, LE ;
Jahrling, PB ;
Geisbert, TW .
NATURE MEDICINE, 2005, 11 (07) :786-790
[48]   Ebola virus secretory glycoprotein (sGP) diminishes FcγRIIIB-to-CR3 proximity on neutrophils [J].
Kindzelskii, AL ;
Yang, ZY ;
Nabel, GJ ;
Todd, RF ;
Petty, HR .
JOURNAL OF IMMUNOLOGY, 2000, 164 (02) :953-958
[49]  
KOBINGER GP, 2005, VIROLOGY
[50]   Clinical virology of Ebola hemorrhagic fever (EHF): Virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995 [J].
Ksiazek, TG ;
Rollin, PE ;
Williams, AJ ;
Bressler, DS ;
Martin, ML ;
Swanepoel, R ;
Burt, FJ ;
Leman, PA ;
Khan, AS ;
Rowe, AK ;
Mukunu, R ;
Sanchez, A ;
Peters, CJ .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 :S177-S187